Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1997 1
2001 2
2002 2
2003 4
2004 4
2005 5
2007 4
2008 3
2009 5
2010 5
2011 3
2012 7
2013 4
2014 7
2015 8
2016 8
2017 11
2018 6
2019 18
2020 16
2021 20
2022 19
Text availability
Article attribute
Article type
Publication date

Search Results

153 results
Results by year
Filters applied: . Clear all
Page 1
Systemic sclerosis-associated interstitial lung disease.
Perelas A, Silver RM, Arrossi AV, Highland KB. Perelas A, et al. Among authors: highland kb. Lancet Respir Med. 2020 Mar;8(3):304-320. doi: 10.1016/S2213-2600(19)30480-1. Epub 2020 Feb 27. Lancet Respir Med. 2020. PMID: 32113575 Review.
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Distler O, et al. Among authors: highland kb. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112379 Free article. Clinical Trial.
Lymphocytic Interstitial Pneumonia.
Panchabhai TS, Farver C, Highland KB. Panchabhai TS, et al. Among authors: highland kb. Clin Chest Med. 2016 Sep;37(3):463-74. doi: 10.1016/j.ccm.2016.04.009. Epub 2016 Jun 25. Clin Chest Med. 2016. PMID: 27514593 Review.
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM; SENSCIS trial investigators. Highland KB, et al. Lancet Respir Med. 2021 Jan;9(1):96-106. doi: 10.1016/S2213-2600(20)30330-1. Lancet Respir Med. 2021. PMID: 33412120 Free article. Clinical Trial.
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators. Tashkin DP, et al. Among authors: highland k. Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25. Lancet Respir Med. 2016. PMID: 27469583 Free PMC article. Clinical Trial.
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O; SENSCIS trial investigators. Seibold JR, et al. Among authors: highland kb. Ann Rheum Dis. 2020 Nov;79(11):1478-1484. doi: 10.1136/annrheumdis-2020-217331. Epub 2020 Aug 5. Ann Rheum Dis. 2020. PMID: 32759258 Free PMC article. Clinical Trial.
Thoracic Manifestations of Rheumatic Disease.
Antin-Ozerkis D, Highland KB. Antin-Ozerkis D, et al. Among authors: highland kb. Clin Chest Med. 2019 Sep;40(3):xiii. doi: 10.1016/j.ccm.2019.05.013. Clin Chest Med. 2019. PMID: 31376901 No abstract available.
Pulmonary arterial hypertension.
Highland KB. Highland KB. Am J Med Sci. 2008 Jan;335(1):40-5. doi: 10.1097/MAJ.0b013e31815d2647. Am J Med Sci. 2008. PMID: 18195582 Review.
153 results